Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced a poster presentation at the 20 th Congress of the European Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025 , in Berlin, Germany , showing that combined inhibition of a4ß7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates (NHPs). "We are thrilled to share these recent preclinical findings supporting the combination potential for our SPY120 program (anti-a4ß7 and anti-TL1A). We tested mouse surrogates of SPY120 in two in vivo models of IBD, demonstrating that combined inhibition of the a4ß7 integrin and TL1A cytokine provide additive or greater than additive efficacy relative to inhibition of either target alone," said Andy S
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.MarketBeat
- Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Mizuho to a "strong-buy" rating.MarketBeat
- Spyre Therapeutics (NASDAQ:SYRE) was given a new $53.00 price target on by analysts at Mizuho.MarketBeat
- Spyre Therapeutics (NASDAQ:SYRE) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 12/3/25 - Form 4
- 11/5/25 - Form 4
- 11/4/25 - Form 8-K
- SYRE's page on the SEC website